Gene: EPB41L3

23136
4.1B|DAL-1|DAL1
erythrocyte membrane protein band 4.1 like 3
protein-coding
18p11.31
Ensembl:ENSG00000082397 MIM:605331 Vega:OTTHUMG00000131562 UniprotKB:Q9Y2J2
NC_000018.10
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.905e-1 (AD)  5.031e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs10221410chr18:5605990 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg06459104chr18:5456880EPB41L31.700e-8Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PPM1H0.961
SRPK20.954
MAPK90.953
DYNC1I10.951
DNAJC60.949
ZNF3650.949
RCAN20.949
MFSD60.947
AK50.946
ATP1B10.945

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LRAT-0.488
EVC2-0.485
RNF135-0.48
RHOD-0.472
CSAG1-0.467
HEY2-0.462
MTRNR2L10-0.457
GJB2-0.457
CHST14-0.453
OR4F5-0.448

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of EPB41L3 mRNA19933214
C0094072,5,2',5'-tetrachlorobiphenyl"2,5,2',5'-tetrachlorobiphenyl results in increased expression of EPB41L3 mRNA"23829299
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of EPB41L3 mRNA"21346803
C0303702-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in increased expression of EPB41L3 mRNA"20206263
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of EPB41L3 gene27153756
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of EPB41L3 mRNA28522335
D000643Ammonium ChlorideAmmonium Chloride affects the expression of EPB41L3 mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of EPB41L3 mRNA24449571
D001151ArsenicArsenic affects the expression of EPB41L3 mRNA18414638
D001194AsbestosAsbestos results in decreased expression of EPB41L3 mRNA21563230
C547126AZM551248AZM551248 results in increased expression of EPB41L3 mRNA22323515
C487081belinostatbelinostat results in increased expression of EPB41L3 mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in decreased expression of EPB41L3 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of EPB41L3 mRNA20713471
D004958EstradiolEstradiol results in increased expression of EPB41L3 mRNA19484750
C006780bisphenol Abisphenol A affects the methylation of EPB41L3 promoter27334623
C006780bisphenol Abisphenol A results in decreased expression of EPB41L3 mRNA26063408
C006780bisphenol Abisphenol A affects the expression of EPB41L3 mRNA25181051
D019256Cadmium Chloride[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA12634122
D019256Cadmium ChlorideCadmium Chloride results in increased methylation of EPB41L3 promoter22457795
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of EPB41L3 mRNA27339419
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of EPB41L3 mRNA23650126
C023600chromic oxide[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA12634122
C017133chromous chloride[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA12634122
C018021cobaltous chloridecobaltous chloride results in decreased expression of EPB41L3 mRNA19320972
D003471CuprizoneCuprizone results in decreased expression of EPB41L3 mRNA26577399
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of EPB41L3 mRNA23914054
C014347decitabinedecitabine affects the expression of EPB41L3 mRNA17260099
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of EPB41L3 mRNA21266533
D002945CisplatinCisplatin results in increased expression of EPB41L3 mRNA27594783
D004052DiethylnitrosamineDiethylnitrosamine affects the expression of EPB41L3 mRNA17428255
D002117CalcitriolCalcitriol results in increased expression of EPB41L3 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of EPB41L3 mRNA21592394
C118739entinostatentinostat results in increased expression of EPB41L3 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of EPB41L3 mRNA17557909
D005047EtoposideEPB41L3 protein affects the susceptibility to Etoposide16217747
D005472FluorouracilFluorouracil affects the expression of EPB41L3 mRNA20421339
D005557FormaldehydeFormaldehyde results in increased expression of EPB41L3 mRNA27664576
D017313FenretinideFenretinide results in increased expression of EPB41L3 mRNA28973697
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of EPB41L3 mRNA25613284
C098607JP8 aviation fuelJP8 aviation fuel results in increased expression of EPB41L3 protein17337753
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of EPB41L3 mRNA24796395
D007854LeadLead affects the splicing of EPB41L3 mRNA28903495
C008261lead acetate[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA12634122
D015122MercaptopurineMercaptopurine results in decreased expression of EPB41L3 mRNA23358152
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
D008627Mercuric ChlorideMercuric Chloride results in decreased expression of EPB41L3 mRNA16507785
D008727MethotrexateMethotrexate affects the expression of EPB41L3 mRNA18502557
C013598methoxyacetic acidmethoxyacetic acid affects the expression of EPB41L3 mRNA20421339
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of EPB41L3 mRNA28001369
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of EPB41L3 mRNA"20188158
D015735MifepristoneMifepristone results in increased expression of EPB41L3 mRNA17584828
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate affects the expression of EPB41L3 mRNA21195148
C028577monobutyl phthalatemonobutyl phthalate affects the expression of EPB41L3 mRNA20421339|2119514
C406082monomethylarsonous acidmonomethylarsonous acid results in increased expression of EPB41L3 protein24625837
D019829NevirapineNevirapine results in decreased expression of EPB41L3 mRNA23947594
D009532NickelNickel results in increased expression of EPB41L3 mRNA24768652|2558310
D009532NickelNickel results in decreased expression of EPB41L3 mRNA12540486
C025256nonylphenolnonylphenol results in decreased expression of EPB41L3 mRNA22982499
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of EPB41L3 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of EPB41L3 mRNA26272509
C006253pirinixic acidpirinixic acid results in decreased expression of EPB41L3 mRNA17426115
D010936Plant ExtractsPlant Extracts results in increased expression of EPB41L3 mRNA23557933
D011192Potassium DichromatePotassium Dichromate results in decreased expression of EPB41L3 mRNA23608068
D011441PropylthiouracilPropylthiouracil results in decreased expression of EPB41L3 mRNA24780913
C059514resveratrolresveratrol results in increased expression of EPB41L3 mRNA25905778
D012822Silicon DioxideSilicon Dioxide results in decreased expression of EPB41L3 mRNA22431001
C017947sodium arsenite[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA12634122
D012969Sodium FluorideSodium Fluoride results in decreased expression of EPB41L3 protein28918527
C075117squalestatin 1squalestatin 1 results in decreased expression of EPB41L3 mRNA27225895
C075117squalestatin 1squalestatin 1 results in decreased expression of EPB41L3 mRNA27225895
D014284Triiodothyronine[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA14761676
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of EPB41L3 mRNA21592394
D013739TestosteroneTestosterone results in increased expression of EPB41L3 mRNA21592394
D013749Tetrachlorodibenzodioxin[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA14761676
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of EPB41L3 mRNA24680724|2637764
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of EPB41L3 mRNA19933214
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of EPB41L3 mRNA25613284
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of EPB41L3 mRNA20133372
D014212TretinoinTretinoin results in increased expression of EPB41L3 mRNA21934132
D014212TretinoinTretinoin affects the expression of EPB41L3 mRNA20421339
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of EPB41L3 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of EPB41L3 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of EPB41L3 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased methylation of EPB41L3 gene29154799
D014635Valproic AcidValproic Acid affects the expression of EPB41L3 mRNA20421339
D001335Vehicle EmissionsVehicle Emissions affects the methylation of EPB41L3 gene25560391
C025643vinclozolinvinclozolin affects the expression of EPB41L3 mRNA19015723
C029297vinylidene chloridevinylidene chloride results in decreased expression of EPB41L3 mRNA26682919

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003779actin binding-IEA-  
GO:0005200structural constituent of cytoskeleton-TAS21966409  
GO:0005515protein binding-IPI12234973  15324660  17353931  20936779  24255178  24366813  
GO ID GO Term Qualifier Evidence PubMed
GO:0001558regulation of cell growth-IEA-  
GO:0002175protein localization to paranode region of axon-ISS-  
GO:0006915apoptotic process-IEA-  
GO:0007016cytoskeletal anchoring at plasma membrane-TAS21966409  
GO:0008150biological_process-ND-  
GO:0008360regulation of cell shape-ISS-  
GO:0030865cortical cytoskeleton organization-TAS21966409  
GO:0030866cortical actin cytoskeleton organization-IEA-  
GO:0030913paranodal junction assembly-ISS-  
GO:0031032actomyosin structure organization-IBA21873635  
GO:0043217myelin maintenance-ISS-  
GO:0048812neuron projection morphogenesis-ISS-  
GO:0071205protein localization to juxtaparanode region of axon-ISS-  
GO:0072659protein localization to plasma membrane-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005829cytosol-TAS-  
GO:0005856cytoskeleton-IBA21873635  
GO:0005886plasma membrane-IDA-  
GO:0005886plasma membrane-NAS9892180  
GO:0005911cell-cell junction-IDA12234973  
GO:0014069postsynaptic density-IEA-  
GO:0030673axolemmacolocalizes_withISS-  
GO:0033270paranode region of axon-ISS-  
GO:0044224juxtaparanode region of axon-ISS-  
KEGG ID KEGG Term
hsa04530Tight junction
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemTAS
R-HSA-6794361Neurexins and neuroliginsTAS
R-HSA-6794362Protein-protein interactions at synapsesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal